NEOT Neothetics, Inc.

1.60
+0.13  (8.84%)
Previous Close 1.47
Open 1.47
Price To book 1.48
Market Cap 22.12M
Shares 13,828,000
Volume 275,325
Short Ratio 1.96
Av. Daily Volume 152,813

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 endpoints not met December 2015. Phase 2 trial initiated December 23, 2016 with data due late 2Q 2017.
LIPO-202
Reduction of localized fat deposits under the chin (submental fat)
Phase 2 trial planned pending data from submental trial.
LIPO-202
Reduction of central abdominal bulging

Latest News

  1. NEOTHETICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  2. Neothetics (NEOT) Begins Phase II Study on Lead Candidate
  3. Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
  4. Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
  5. NEOTHETICS, INC. Financials
  6. Neothetics Provides Business Update and Reports Third Quarter 2016 Financial Results
  7. NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  8. Neothetics to Provide a Business Update and Release Third Quarter 2016 Financial Results Thursday, November 10, 2016
  9. NEOTHETICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement
  10. Neothetics Provides Business Update and Reports Second Quarter 2016 Financial Results
  11. NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  12. Neothetics to Provide a Business Update and Release Second Quarter 2016 Financial Results Thursday, August 11, 2016
  13. NEOTHETICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
  14. NEOTHETICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
  15. 6 Stocks Under $10 Making Big Moves Higher
  16. 5 Breakout Stocks Under $10 Set to Soar
  17. Neothetics Reports First Quarter 2016 Financial Results
  18. NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  19. Neothetics to Release First Quarter 2016 Financial Results
  20. Stocks To Watch: Investors Are Considering These on Monday April 25th

SEC Filings

  1. 8-K - Current report 17609634
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17582546
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17515095
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161986057
  5. 8-K - Current report 161986042
  6. 8-K - Current report 161900191
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161823046
  8. 8-K - Current report 161823036
  9. 8-K - Current report 161718881
  10. 8-K - Current report 161697534